Cost per responder for upadacitinib vs abatacept in pati ents with moderate-to-severe Rheumatoid Arthritis in Italy (vol 8, pg 69, 2021)

被引：0

|

作者：

Caporali, Roberto ^{[1
,2
]}

Ravasio, Roberto ^{[3
]}

Raimondo, Paola ^{[3
]}

Salaffi, Fausto ^{[4
]}

机构：

[1] Univ Milan, Dept Clin & Community Sci DISCCO, Milan, Italy

[2] ASST Pini COT, Dept Rheumatol & Med Sci, Milan, Italy

[3] Market Access Provider, Milan, Italy

[4] Univ Politecn Marche, Carlo Urbani Hosp, Dept Clin & Mol Sci, Rheumatol Clin, Jesi, AN, Italy

来源：

GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT | 2022年 / 9卷

关键词：

D O I：

10.33393/grhta.2022.2383

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

引用

收藏

页码：30 / 30

页数：1

相关论文

共 24 条

[21] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (vol 397, pg 2169, 2021)
Reich, K.
Teixeira, H. D.
de Bruin-Weller, M.
LANCET, 2021, 398 (10302): : 746 - 746
[22] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (vol 397, pg 2169, 2021)
Reich, K.
Teixeira, H. D.
de Bruin-Weller, M.
LANCET, 2021, 397 (10292): : 2336 - 2336
[23] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (MeasureUp 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials (vol 397, pg 2151, 2021)
Guttman-Yassky, E.
Teixeira, H. D.
Simpson, E. L.
Katoh, Norito
LANCET, 2021, 397 (10290): : 2150 - 2150
[24] Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy:The FINCH2 Randomized Clinical Trial (vol 322, pg 315, 2019)
Genovese, M. C.
Kalunian, K.
Gottenberg, J-E
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (05): : 480 - 480